Recent pharmacological innovations like angiotensin receptor neprilysin inhibitors (ARNIs) have improved therapy for heart failure patients with reduced ejection fraction (HFrEF). However, patients with HFrEF and heart failure with preserved ejection fraction (HFpEF) still suffer from dyspnoea on exertion and reduced quality of life. HFpEF accounts for more than 50% of all heart failure (HF) patients and is associated with high morbidity and mortality. There are only very limited treatment options to improve outcomes.1–3
展开▼
